ACRV Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 11.90%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $3,009,858.24

Acrivon Therapeutics Insider Trading History Chart

Acrivon Therapeutics Share Price & Price History

^$2.41

▲ +0.13 (5.70%)

As of 12/4/2025 05:00 PM ET

Days: 30 | 90 | 365

Acrivon Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/30/2025	Perceptive Advisors Llc	Major Shareholder	Sell	437,881	$1.41	$617,412.21	3,403,025
4/28/2025	Perceptive Advisors Llc	Major Shareholder	Sell	215,283	$1.56	$335,841.48	4,090,906
4/25/2025	Perceptive Advisors Llc	Major Shareholder	Sell	1,054,669	$1.95	$2,056,604.55	4,306,189
4/11/2024	Perceptive Advisors Llc	Major Shareholder	Buy	2,353,000	$8.50	$20,000,500.00	5,360,858
6/26/2023	Ltd Chione	Major Shareholder	Sell	16	$12.93	$206.88	3,848,632
6/14/2023	Ltd Chione	Major Shareholder	Sell	893	$12.13	$10,832.09	3,850,704
6/12/2023	Ltd Chione	Major Shareholder	Sell	2,000	$12.34	$24,680.00	3,854,597

SEC Filings (Institutional Ownership Changes) for Acrivon Therapeutics (NASDAQ:ACRV)

71.62% of Acrivon Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Acrivon Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/17/2025	Millennium Management LLC	185,234	$0.34M	0.0%	-37.5%	0.589%
11/17/2025	Focus Partners Wealth	19,846	$36K	0.0%	N/A	0.063%
11/17/2025	Citadel Advisors LLC	1,541,326	$2.79M	0.0%	-18.7%	4.900%
11/17/2025	Algert Global LLC	44,648	$81K	0.0%	N/A	0.141%
11/14/2025	Two Sigma Investments LP	319,205	$0.58M	0.0%	+76.2%	1.015%
11/14/2025	Squarepoint Ops LLC	104,324	$0.19M	0.0%	-31.6%	0.332%
11/13/2025	UBS Group AG	683,218	$1.24M	0.0%	+150,057.8%	2.172%
8/15/2025	Bridgeway Capital Management LLC	22,900	$27K	0.0%	-70.6%	0.073%
8/14/2025	Jane Street Group LLC	311,829	$0.37M	0.0%	N/A	0.995%
8/13/2025	Marshall Wace LLP	181,187	$0.22M	0.0%	-59.8%	0.578%
8/13/2025	Quadrature Capital Ltd	22,175	$26K	0.0%	N/A	0.071%
8/12/2025	XTX Topco Ltd	106,119	$0.13M	0.0%	N/A	0.338%
8/8/2025	Geode Capital Management LLC	164,362	$0.20M	0.0%	-46.3%	0.524%
6/27/2025	Goldman Sachs Group Inc.	57,519	$0.12M	0.0%	-75.8%	0.183%
5/16/2025	Goldman Sachs Group Inc.	57,519	$0.12M	0.0%	-75.8%	0.183%
5/15/2025	Baker BROS. Advisors LP	22,809	$46K	0.0%	-56.9%	0.073%
5/13/2025	Wealthedge Investment Advisors LLC	56,467	$0.12M	0.1%	+420.1%	0.180%
5/12/2025	Nuveen LLC	13,402	$27K	0.0%	N/A	0.043%
5/12/2025	Invesco Ltd.	35,315	$72K	0.0%	N/A	0.113%
3/12/2025	Wealthedge Investment Advisors LLC	10,857	$65K	0.0%	N/A	0.035%
2/17/2025	Nuveen Asset Management LLC	13,402	$81K	0.0%	-48.0%	0.043%
2/17/2025	OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC	102,784	$0.62M	0.0%	+29.7%	0.330%
2/17/2025	Corton Capital Inc.	12,159	$73K	0.0%	N/A	0.039%
2/17/2025	Bridgeway Capital Management LLC	74,600	$0.45M	0.0%	-3.1%	0.240%
2/17/2025	Citadel Advisors LLC	2,119,646	$12.76M	0.0%	-1.0%	6.807%
2/17/2025	Acorn Capital Advisors LLC	405,237	$2.44M	1.3%	N/A	1.301%
2/14/2025	Northern Trust Corp	117,323	$0.71M	0.0%	+11.3%	0.377%
2/14/2025	Dimensional Fund Advisors LP	37,063	$0.22M	0.0%	+20.2%	0.119%
2/13/2025	Marshall Wace LLP	597,794	$3.60M	0.0%	-26.2%	1.920%
2/13/2025	Barclays PLC	38,091	$0.23M	0.0%	+14.4%	0.122%
2/13/2025	Renaissance Technologies LLC	49,400	$0.30M	0.0%	+7.6%	0.159%
2/12/2025	Trexquant Investment LP	16,871	$0.10M	0.0%	-44.5%	0.054%
2/12/2025	JPMorgan Chase & Co.	25,809	$0.16M	0.0%	-24.1%	0.083%
2/11/2025	American Century Companies Inc.	17,588	$0.11M	0.0%	+14.2%	0.056%
2/6/2025	Charles Schwab Investment Management Inc.	113,840	$0.69M	0.0%	-2.1%	0.366%
2/4/2025	Bank of New York Mellon Corp	27,635	$0.17M	0.0%	-6.4%	0.089%
1/24/2025	China Universal Asset Management Co. Ltd.	6,602	$40K	0.0%	N/A	0.021%
12/26/2024	JPMorgan Chase & Co.	33,991	$0.24M	0.0%	+548.3%	0.109%
12/13/2024	Exome Asset Management LLC	116,757	$0.82M	0.5%	N/A	0.375%
11/19/2024	Barclays PLC	33,306	$0.23M	0.0%	+51.2%	0.107%
11/16/2024	Geode Capital Management LLC	302,103	$2.12M	0.0%	-2.0%	0.975%
11/15/2024	Barclays PLC	33,306	$0.23M	0.0%	+51.2%	0.108%
11/15/2024	State Street Corp	225,896	$1.58M	0.0%	+26.4%	0.729%
11/12/2024	Charles Schwab Investment Management Inc.	116,253	$0.81M	0.0%	-19.2%	0.375%
10/10/2024	Exchange Traded Concepts LLC	20,348	$0.14M	0.0%	-52.5%	0.066%
8/16/2024	Perceptive Advisors LLC	5,360,858	$31.09M	0.7%	+78.2%	17.362%
8/14/2024	Marshall Wace LLP	948,866	$5.50M	0.0%	+58.8%	3.073%
8/13/2024	Sands Capital Ventures LLC	2,122,605	$12.31M	4.1%	+28.4%	6.874%
8/12/2024	XTX Topco Ltd	10,493	$61K	0.0%	N/A	0.034%
8/9/2024	Renaissance Technologies LLC	54,500	$0.32M	0.0%	-46.9%	0.177%
8/9/2024	Dimensional Fund Advisors LP	10,066	$58K	0.0%	N/A	0.033%
8/1/2024	Rhumbline Advisers	16,209	$94K	0.0%	+48.9%	0.052%
7/26/2024	Bank of New York Mellon Corp	36,632	$0.21M	0.0%	+50.1%	0.119%
5/15/2024	Baker BROS. Advisors LP	52,885	$0.38M	0.0%	N/A	0.234%
5/14/2024	American International Group Inc.	6,016	$43K	0.0%	+39.2%	0.027%
5/10/2024	Vanguard Group Inc.	507,185	$3.63M	0.0%	+6.6%	2.241%
1/5/2024	Exchange Traded Concepts LLC	13,289	$65K	0.0%	+34.0%	0.060%
11/13/2023	Federated Hermes Inc.	226,375	$2.16M	0.0%	-25.6%	1.020%
9/21/2023	Barclays PLC	14,263	$0.18M	0.0%	-16.0%	0.065%
8/10/2023	AAF Wealth Management LLC	10,678	$0.14M	0.1%	N/A	0.049%
7/20/2023	Exchange Traded Concepts LLC	11,709	$0.15M	0.0%	N/A	0.053%
5/8/2023	Federated Hermes Inc.	613,625	$7.79M	0.0%	-25.5%	2.798%
2/16/2023	HealthCor Management L.P.	284,201	$3.27M	3.0%	N/A	1.360%
2/14/2023	RA Capital Management L.P.	4,810,508	$55.42M	1.1%	N/A	23.028%
2/13/2023	Sands Capital Ventures LLC	1,652,605	$19.04M	5.2%	N/A	7.913%
2/10/2023	NEA Management Company LLC	481,677	$4.44M	0.2%	N/A	2.306%
2/1/2023	Bank of Montreal Can	42,444	$0.55M	0.0%	N/A	0.203%

Data available starting January 2016

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Today's Range

Now: $2.41

$2.25

$2.55

50 Day Range

MA: $2.06

$1.66

$2.43

52 Week Range

Now: $2.41

$1.05

$8.00

Volume

593,156 shs

Average Volume

577,323 shs

Market Capitalization

$76.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.75

Who are the company insiders with the largest holdings of Acrivon Therapeutics?: Acrivon Therapeutics' top insider shareholders include:
Perceptive Advisors Llc (Major Shareholder)
Learn More about top insider investors at Acrivon Therapeutics.
Who are the major institutional investors of Acrivon Therapeutics?: Acrivon Therapeutics' top institutional investors include:
Citadel Advisors LLC — 4.90%
UBS Group AG — 2.17%
Two Sigma Investments LP — 1.01%
Millennium Management LLC — 0.59%
Squarepoint Ops LLC — 0.33%
Algert Global LLC — 0.14%
Learn More about top institutional investors of Acrivon Therapeutics stock.
Which major investors are selling Acrivon Therapeutics stock?: In the previous quarter, ACRV stock was sold by these institutional investors:
Citadel Advisors LLC
Millennium Management LLC
Squarepoint Ops LLC
Which major investors are buying Acrivon Therapeutics stock?: In the previous quarter, ACRV stock was bought by institutional investors including:
UBS Group AG
Two Sigma Investments LP
Algert Global LLC
Focus Partners Wealth